Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” [Dig. Liver Dis. 48 (2016) 360–370]

2016 ◽  
Vol 48 (9) ◽  
pp. 1103
Author(s):  
Alessandro Armuzzi ◽  
Paolo Gionchetti ◽  
Marco Daperno ◽  
Silvio Danese ◽  
Ambrogio Orlando ◽  
...  
2016 ◽  
Vol 48 (4) ◽  
pp. 360-370 ◽  
Author(s):  
Alessandro Armuzzi ◽  
Paolo Gionchetti ◽  
Marco Daperno ◽  
Silvio Danese ◽  
Ambrogio Orlando ◽  
...  

2019 ◽  
Vol 50 (11-12) ◽  
pp. 1204-1213 ◽  
Author(s):  
Gaëlle Varkas ◽  
Clio Ribbens ◽  
Edouard Louis ◽  
Filip Van den Bosch ◽  
Rik Lories ◽  
...  

2021 ◽  
Vol 78 (2) ◽  
pp. 117-128
Author(s):  
Yoo Jin Lee ◽  
Seong-Eun Kim ◽  
Yong Eun Park ◽  
Ji Young Chang ◽  
Hyun Joo Song ◽  
...  

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S074-S074
Author(s):  
G Doherty ◽  
K Katsanos ◽  
J Burisch ◽  
M Allez ◽  
K Papamichael ◽  
...  

Author(s):  
Johan F K F Ilvemark ◽  
Tawnya Hansen ◽  
Thomas M Goodsall ◽  
Jakob B Seidelin ◽  
Heba Al-Farhan ◽  
...  

Abstract Background and aims No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting. Methods Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts (n=18) rated an initial 196 statements (RAND/UCLA process, scale 1-9). Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively. Results Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included. 83% (40/48) of included studies showed a low concern of applicability, while 96% (46/48) had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease. Conclusions Response criteria and time-points of response assessment varied between studies complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response to incorporate into future prospective studies.


Sign in / Sign up

Export Citation Format

Share Document